{"id":"NCT00603642","sponsor":"Amgen","briefTitle":"P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura","officialTitle":"A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10-01","primaryCompletion":"2009-04-13","completion":"2009-04-13","firstPosted":"2008-01-29","resultsPosted":"2010-12-10","lastUpdate":"2022-11-08"},"enrollment":34,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Thrombocytopenic Purpura"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"AMG 531","otherNames":[]}],"arms":[{"label":"AMG 531","type":"PLACEBO_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura (ITP) .","primaryOutcome":{"measure":"Weeks With Weekly Platelet Response","timeFrame":"12 weeks (Weeks 2 - 13)","effectByArm":[{"arm":"Placebo","deltaMin":0,"sd":null},{"arm":"Romiplostim","deltaMin":11,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":["Nasopharyngitis","Headache","Oedema peripheral","Malaise","Arthralgia"]}}